Researchers have identified a brain inflammation marker in patients at early asymptomatic stages of Alzheimer's disease.This molecule may provide clinicians with a rapidly detectable biomarker for the transition from preclinical Alzheimer's disease to cognitive impairment and progression to full dementia.


